Recordati Rare Diseases Introduces New PANHEMATIN(R) (Hemin for Injection) Dosage Strength for Treatment of Acute Intermittent Porphyria (AIP)
Updated Label Reflects More Than 30 Years of Clinical Experience
LEBANON, N.J., July 5, 2017 -- (Healthcare Sales & Marketing Network) -- Recordati Rare Diseases Inc., a biopharmaceutical company committed to providing orphan therapies to underserved r... Biopharmaceuticals, Product Launch Recordati Rare Diseases, PANHEMATIN, hemin, Porphyria
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Lebanon Health | Marketing | Middle East Health | Pharmaceuticals | Porphyria | Rare Diseases